A Longitudinal Study in Parkinson's Disease (PD) Patients
A Longitudinal 5 Years Follow up Study in Parkinson's Disease (PD) Patients Carriers of the LRRK2 Gene G2019S Mutation
1 other identifier
observational
200
1 country
1
Brief Summary
This is a longitudinal study in patients with Parkinson's Disease (PD) carriers of a genetic mutation - substitution of gly with ser in position 2019 (G2019S) in the leucine-rich repeat kinase 2 (LRRK2) gene. The purpose of this study is to explore the association between genetic mutations in the known genes and their influence on disease manifestation over few years of follow up
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 22, 2012
CompletedStudy Start
First participant enrolled
November 1, 2012
CompletedFirst Posted
Study publicly available on registry
November 21, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2015
CompletedNovember 21, 2012
November 1, 2012
2.6 years
October 22, 2012
November 15, 2012
Conditions
Outcome Measures
Primary Outcomes (1)
change from baseline in updrs motor and total scores
the participants will be followed for 5 years. the measurements will be taken evry 18 month.
Study Arms (1)
PD patients
PD patients carriers of the G2019S mutation in the LRRK2 gene
Interventions
Eligibility Criteria
PD patients carriers of the G2019S mutation in the LRRK2 gene
You may qualify if:
- parkinson'd disease patients that already participated in a pasr cross sectional study
You may not qualify if:
- subjects with cognitive decline by the parameters defined in Diagnostic and Statistical Manual of Mental Disorders (DSM)- IV
- subjects with psychiatric disorder
- subjects unable to sign a consent form
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 22, 2012
First Posted
November 21, 2012
Study Start
November 1, 2012
Primary Completion
June 1, 2015
Last Updated
November 21, 2012
Record last verified: 2012-11